Kura Oncology launches Caspian Therapeutics with $50M funding to develop menin inhibitors for diabetes and cardiometabolic ...

Independent research teams validate Apeximmune's PLA2G2D as key to overcoming anti-PD-1 resistance in cancer therapy. Read ...

BioNTech halts autogene cevumeran Phase II trial after safety board finds imbalance favoring control arm in colorectal cancer ...

Lee's Pharmaceutical licenses preclinical PARP1 inhibitor OC-3 from 1cBio for Greater China and Southeast Asia. Exclusive ...

TwoStep Therapeutics secures $62.5M Series A funding and FDA IND clearance for TS-104, a first-in-class peptide-drug ...

Alebund Pharmaceuticals receives FDA IND clearance for AP308, an engineered IgA protease for IgA nephropathy treatment. Phase ...

Solstice Oncology secures $225M Series A to advance porustobart, a next-gen CTLA-4 antibody for neoadjuvant cancer treatment.

Assembly Bio exercises option to shift HSV helicase-primase inhibitor program from royalty deal to 40% US profit-share with ...

Schrödinger launches Tectora Therapeutics with $55M Series A funding to advance immunology and inflammation programs. Learn ...

Leyden Labs' RIG-101 shows positive Phase I results with safety and immune activation. Company advances to Phase II ...

Evommune's EVO756 fails second consecutive Phase IIb trial, eliminating lead indications. Read the latest biotech news on ...

Beam Therapeutics' BEAM-302 gene therapy maintains protective alpha-1 antitrypsin levels for 18 months in Phase I/II trial.